On Apr. 22, United Treatment Centers OTCPINK: UTRM), an internet-based news content provider for the marijuana industry, share volume soared with 209,687,484 shares changing hands, significantly higher than its three-month average volume of 180,872,801 shares.
The uptick in volume is being fueled in part by the Los Angeles-based company’s unveiling of its new website and daily video production component.
The website will serve as the main portal for news regarding the marijuana industry. Daily video broadcasts will keep viewers up to date with relevant information and commentary. The show launched on Apr. 20 with its first news video.
Using streaming technology, videos will be disseminated globally through the website and social media outlets. The show will be informative, covering all aspects of the marijuana industry, presented in a style tailored to the interests of the audience.
Additionally, the website will offer compliance packages and insurance for those looking to break into the marijuana industry. The website also provides a great opportunity for marijuana businesses to market products and services.
CEO Chris Seminatore stated, "I deeply appreciate all the hard work from our team that has gone into the launch of the website. Our core competencies are video production and providing business services to the marijuana industry." He went on to say that, "This is just the beginning for PotNetwork.tv. We have so much more coming your way in the upcoming weeks. Please stay tuned."
On Apr. 22, UTRM’s share price closed at 0.0065 cents, up 0.0009 cents from its closing price of 0.0062 cents the previous day.
Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:
Creative Edge Nutrition Inc. Appoints John A. Germinario Chairman of the Board
In other news, Creative Edge Nutrition Inc. (OTCPINK: FITX) and CEN Biotech, a partially owned subsidiary of Creative Edge, announced the appointment of John A. Germinario as Chairman of the Board of Directors effective immediately.
As a seasoned banker with over 33 years of experience in global capital markets, Mr. Germinario will be managing a variety of immediate tasks including regulatory compliance, risk management, corporate governance, potential mergers and acquisitions, assessing market strategy and spearheading financing activities.
Mr. Germinario currently serves as CEO of Global Securities Services Corporation an international strategic institution focused on designing and implementing Depositary Receipt Programs for publicly traded companies. Prior to joining CEN Biotech, Mr. Germinario was a global capital markets securities fraud examiner and worked with the U.S. Securities and Exchange Commission (SEC) and the Internal Revenue Service (IRS) Whistleblower to identify multiple levels of securities, bank and tax fraud, resulting in the collection of hundreds of millions of dollars in unpaid taxes by four major New York banks.
On Apr.22, FITX shares closed at 9 cents unchanged from its closing price the previous day.
GW Pharmaceuticals Plc’s Stock Volume Soars
Meanwhile, GW Pharmaceuticals Plc.’s (OTCPINK: GWPRF) stock volume also soared Apr. 22, with 223,893 shares changing hands, three times its three-month average of 75,930 shares.
The London-based pharmaceutical share volume had been surging on the heels of a recent announcement the company made that the Food and Drug Administration (FDA) has granted orphan drug designation for Epidiolex(R). This is GW’s product candidate that contains plant-derived Cannabidiol (CBD) as its active ingredient, for use in treating children with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.
There has been no recent or past negative news, so why this is happening is anybody’s guess.
In November 2013, GW announced that the FDA had granted orphan drug designation for Epidiolex in the treatment of Dravet syndrome.
Following the successful follow-on offering completed in January 2014, GW intends to advance a full clinical development program for Epidiolex for the treatment of both LGS and Dravet syndromes. Working with leading pediatric epilepsy specialists in the United States,
GW expects to commence an initial Phase 2 clinical trial for Epidiolex in the second half of 2014. This trial, if successful, is expected to lead to Phase 3 pivotal trial programs in both Dravet syndrome and LGS intended to support New Drug Applications with the FDA.
On Apr. 22, GWPRF’s share price closed at $5.12, up $1.31 from its closing price of $3.81 the previous day.
Cannabis Sativa Inc. Completes Merger with Wild Earth Naturals Inc.
Finally, Cannabis Sativa Inc. (OTCQB: CBDS) is a company in the developmental stage. It recently acquired Wild Earth Naturals Inc. and has since sold off its sun tanning business.
"The successful completion of the merger represents a major milestone for Wild Earth Naturals, positioning the company for growth," said David Tobias, President. We believe this ‘going-public’ transaction will enable us to grow our business"
That is the extent of the public information available about the Mesquite, NV-based company. It latest financials covering the period ending Dec. 31, 2013, the company showed a $32-million loss.
On Apr. 22, CBDS’s share price closed at $6.00, up $1.99 from its closing price of $4.01 the previous day.
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed. Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership. Simply sign up for free and start receiving exclusive alerts. Subscribe Here: http://www.pennypickalerts.com
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.